| Dr Bernard Amiel Harris, MD,MPH | |
|
1128 Main St Apt 1f, Darby, PA 19023-1230 | |
| (484) 680-7575 | |
| (570) 309-0190 |
| Full Name | Dr Bernard Amiel Harris |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Addiction Medicine |
| Location | 1128 Main St Apt 1f, Darby, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619081726 | NPI | - | NPPES |
| 01-0935702 | Medicaid | PA |
| Entity Name | Creative Health Services, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124194121 PECOS PAC ID: 2365340528 Enrollment ID: O20040109000892 |
News Archive
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).
Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).
Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
› Verified 6 days ago
| Entity Name | West Phila Community Mental Health Consortium, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194757989 PECOS PAC ID: 9638072580 Enrollment ID: O20040129000191 |
News Archive
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).
Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).
Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
› Verified 6 days ago
| Entity Name | Ars Treatment Centers Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346731171 PECOS PAC ID: 0042568131 Enrollment ID: O20180807000056 |
News Archive
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).
Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).
Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
› Verified 6 days ago
| Entity Name | The Md Telemedicine Network Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205599453 PECOS PAC ID: 2961891759 Enrollment ID: O20220628003366 |
News Archive
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).
Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).
Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bernard Amiel Harris, MD,MPH 41 E Providence Rd, Yeadon, PA 19050-2823 Ph: (484) 798-8906 | Dr Bernard Amiel Harris, MD,MPH 1128 Main St Apt 1f, Darby, PA 19023-1230 Ph: (484) 680-7575 |
News Archive
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).
Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).
Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
› Verified 6 days ago
Dr. William B Mcnamee Jr., M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1503 Lansdowne Ave, Suite 3010, Darby, PA 19023 Phone: 610-237-5817 Fax: 610-237-5802 | |
Dr. Andrew W Mcginnis, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1501 Lansdowne Ave, Suite 104, Darby, PA 19023 Phone: 610-534-6150 | |
Dr. Michael Kevin Mcgarry Jr., M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Lansdowne Ave, Darby, PA 19023 Phone: 610-237-4000 | |
Dhruvan Nimish Patel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Lansdowne Ave, Darby, PA 19023 Phone: 610-237-4000 | |
Dr. Kevin Ernest Leahy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 Lansdowne Ave, Darby, PA 19023 Phone: 610-237-4000 | |
Sohiel Deshpande, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Lansdowne Ave, Darby, PA 19023 Phone: 610-237-4000 | |
Celsus Iegbeojai Ebba, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 869 Main St, Darby, PA 19023 Phone: 610-461-2440 Fax: 610-461-2475 |